Fortress Biotech Inc 9.375% Series A Cumulativ (FBIOP) Stock Price, Quote & News

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.fortressbiotech.com

Address:

1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States

Sawnchey Nov. 22 at 11:24 AM

$FBIO $FBIOP Good to see the number of sites online for the Ruby and Topaz Dotinurad trials already. Make no mistake it will not be a 5-minute process with 750 participants and a 64-week endpoint, but at least we are seeing them do everything they can for a speedy enrolment. This is the advantage of having a partner with 200m cash and minimal overheads or parallel programs. In a few years time we could be seeing a nice steady income stream from Unloxcyt, CUTX-101 and Dotinurad royalties.

1 · Reply

StockBodega Nov. 20 at 6:30 PM

$FBIO $FBIOP Picked up some FBIOP on sale today!

1 · Reply

noname5 Nov. 17 at 8:31 PM

$FBIO $FBIOP most recent PRV sold for $175M. This continues the trend of PRVs selling for much higher than the times from 2017-Q1 2024. New FDA voucher program has significantly inc number of vouchers issued by FDA. However, these vouchers are non transferable, meaning there is a decreasing number of transferable vouchers in the market given that the old program has not been renewed. Remains to be seen whether the inc in non transferable vouchers will dec the price of transferable vouchers since the program started in late July, but is a good sign that a voucher sold for $175 in Q3

1 · Reply

makrodimutross Nov. 17 at 2:53 PM

$FBIO $FBIOP Now we see why Zydus believes they will Launch CUTX-101 some time between January and June of next year.

0 · Reply

Sawnchey Nov. 17 at 12:47 PM

$FBIO $FBIOP Based on an expected Cass 2 reubmission, new PDUFA for CUTX-101 expected around June 14th 2026 (30 days to accept filing, 6 months to review). I expect it will be Class 2 as this is usually the case when they need to reinspect the manufacturing site.

1 · Reply

Sawnchey Nov. 17 at 12:39 PM

$FBIO $FBIOP Per today's 8-K filing, the NDA resubmission has already taken place on November 14th. This is excellent news, far quicker than I was expecting. This should hopefully allow response acceptance before the next time period of potential givernment shutdown and a new PDUFA in time to still qualify for PRV issuance.

1 · Reply

makrodimutross Nov. 14 at 6:36 PM

$FBIO $FBIOP It is also interesting to note that Oaktree has exercised half of their warrants.

1 · Reply

makrodimutross Nov. 14 at 4:03 PM

$FBIOP $FBIO Here's where they put Crystalys, and the expired liabilities from Urica. You can see from 2024 how much they've amortized all other intangible assets... this company is an absolute sleeper build.

1 · Reply

makrodimutross Nov. 14 at 3:52 PM

$FBIO $FBIOP close! But SG+A is actually better than i anticipated! 17.4m in Q3! Also like that they've brought the fair value of Crystalys into the financial statements... This is an overall excellent Q, and the pivot to a cashflow positive state is getting closer.

2 · Reply

Sawnchey Nov. 14 at 2:23 PM

$FBIO $FBIOP Nice to be able to review the financials without the legacy element of Checkpoint murkying the waters. Enclosed is (in my opinion) the most important part of the 10-Q. We can see that Journey is coming very close to profitability, Mustang and Avenue are not close to any kind of meaningful product commercialisation but cost almost nothing to keep going. The main Fortress operation is also relatively cheap to run and those Unloxcyt royalties will begin trickling in at some point in the next year and we will hopefully see additional income upon the eventual hopeful success of CUTX-101. In short the situation is very stable while we await the Emrosi growth and any further milestones that can tip the group into sustained profitability. As for the preferred dividend, it is still paused, but the outstanding balance of 10M is not so high that a meaningful milestone can't unlock it in the future. I am going to keep slowly accumulating shares when they look cheap and waiting.

1 · Reply

Market Cap	N/A
Revenue (ttm)	84.51M
Net Income (ttm)	-60.64M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	304
Avg Vol	18,892
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	79%
Beta	N/A
Analysts	Strong Buy
Price Target	N/A